A Phase Ib/II Multicenter Dose-Determination Study, With an Adaptive, Randomized, Placebo-Controlled, Double-Blind Phase II, Using Various Repeated IV Doses of BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients With Prior Skeletal-Related Event.

Trial Profile

A Phase Ib/II Multicenter Dose-Determination Study, With an Adaptive, Randomized, Placebo-Controlled, Double-Blind Phase II, Using Various Repeated IV Doses of BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients With Prior Skeletal-Related Event.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Nov 2014

At a glance

  • Drugs BHQ 880 (Primary) ; Zoledronic acid
  • Indications Multiple myeloma
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 May 2012 Trial phase changed from I/II to II as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top